Raj Satkunasivam, MD, MS, FRCSC

GU Oncology Now

Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, details the RAD VACCINE MIBC trial, a single-arm, phase 2 evaluation of the efficacy and safety of combination neoadjuvant sasanlimab with stereotactic body radiotherapy as an in situ vaccine in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).In his previous comments, Dr. Satkunasivam highlighted traditional treatment approaches for MIBC and the current momentum for an immunotherapy-plus-radiation strategy.View Dr. Satkunasivam&rsquo;s <a href="https://guoncologynow.com/post/dr-raj-satkunasivam-on-mibc-neoadjuvant-approaches-for-local-distant-control" target="_blank" rel="noopener">previous comments</a>.

Dr. Raj Satkunasivam on Neoadjuvant Sasanlimab and SBRT for Cisplatin-Ineligible MIBC

Muscle Invasive Urothelial Carcinoma

Dr. Satkunasivam details the RAD VACCINE MIBC trial, a single-arm, phase 2 evaluation of the efficacy and safety of combination neoadjuvant sasanlimab.

Dr. Raj Satkunasivam on Neoadjuvant Sasanlimab, SBRT for MIBC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe